These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27110020)

  • 1. Effect of Immunosuppressive Therapy on Cardiovascular Risk Factor Prevalence in Kidney-Transplanted Children: Comparative Study.
    García-Bello JA; Romo-Del Río EG; Mendoza-Gómez E; Camarena-Arias PA; Santos-Caballero M
    Transplant Proc; 2016 Mar; 48(2):639-42. PubMed ID: 27110020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients.
    Sessa A; Esposito A; Giliberti A; Iavicoli G; Costa C; Bergallo M; Lettieri E; Rossano R; Capuano M
    Transplant Proc; 2009 May; 41(4):1178-82. PubMed ID: 19460510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience.
    Hsu KH; Chou NK; Tsai MK; Chi NH; Chen YS; Yu HY; Wang CH; Ko WJ; Tsao CI; Lee PH; Wang SS
    Transplant Proc; 2010 Apr; 42(3):934-7. PubMed ID: 20430208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy.
    Charco R; Cantarell C; Vargas V; Capdevila L; Lázaro JL; Hidalgo E; Murio E; Margarit C
    Liver Transpl Surg; 1999 May; 5(3):204-8. PubMed ID: 10226111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus.
    Zawiasa A; Szklarek-Kubicka M; Fijałkowska-Morawska J; Nowak D; Rysz J; Mamełka B; Nowicki M
    Transplant Proc; 2009; 41(1):188-91. PubMed ID: 19249511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors.
    Hohage H; Welling U; Heck M; Zeh M; Gerhardt U; Suwelack BM
    Int Immunopharmacol; 2005 Jan; 5(1):117-23. PubMed ID: 15589469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk estimates and risk factors in renal transplant recipients.
    Krämer BK; Böger C; Krüger B; Marienhagen J; Pietrzyk M; Obed A; Paczek L; Mack M; Banas B
    Transplant Proc; 2005 May; 37(4):1868-70. PubMed ID: 15919488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Study on Mycophenolic Acid Drug Interactions: Effect of Prednisone, Sirolimus, and Tacrolimus With MPA.
    Alvarez-Elías AC; Yoo EC; Todorova EK; Singh RN; Filler G
    Ther Drug Monit; 2017 Jun; 39(3):220-228. PubMed ID: 28437284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric renal transplantation: a single-center experience in northeast Thailand.
    Wisanuyotin S; Jiravuttipong A
    J Med Assoc Thai; 2009 Dec; 92(12):1635-9. PubMed ID: 20043566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.
    Kahvecioglu S; Ersoy A; Gullulu M; Dirican M
    Exp Clin Transplant; 2014 Aug; 12(4):334-42. PubMed ID: 24447269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?
    Deleuze S; Garrigue V; Delmas S; Chong G; Swarcz I; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2311-3. PubMed ID: 16980075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
    Bunnapradist S; Daswani A; Takemoto SK
    Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.